Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nebulized andrographolide sulfonate for pediatric acute respiratory distress syndrome
ChiCTR-IPR-17012450Phase 4Completed
- Sponsor
- Beijing Children's Hospital
- Start
- Sep 2017
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of andrographolide sulfonate in acute respiratory distress syndrome (ARDS) (2 arms), sponsored by Beijing Children's Hospital. Primary endpoint: Case fatality rate. Started Sep 2017; status: completed.
02
Drugs
andrographolide sulfonate
03
Conditions
acute respiratory distress syndrome (ARDS)
Beyond the preview
Go deeper on ChiCTR-IPR-17012450.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-IPR-17012450.